Complications of cirrhosis
Authors:
- Robert S. RahimiRRRobert S. Rahimi
- Don C. RockeyDRDon C. Rockey
- 1 May 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Gastroenterology
- Vol. 28 (3) , 223-229
Abstract
Chronic liver disease (CLD) causes significant morbidity and mortality, mainly due to complications [hepatic encephalopathy, ascites, hepatorenal syndrome (HRS), and esophageal variceal hemorrhage (EVH)]. Studies of the complications, management and outcomes in patients with CLD over the past 18 months are reviewed. Percutaneous liver biopsy can be safely performed in patients with advanced liver disease with minimal complications. Predictors of response to lactulose, probiotics and L-ornithine-L-aspartate therapy in minimal hepatic encephalopathy have been reported. Rifaximin was found to lead to better maintenance of remission and decreased re-admission rates in patients with cirrhosis and hepatic encephalopathy, and may improve driving performance in those with minimal hepatic encephalopathy. In a controversial study, patients with refractory ascites taking propranolol were found to have poorer outcomes, perhaps related to beta-blockade associated paracentesis-induced circulatory dysfunction. Terlipressin and albumin therapy currently appears to be the best medical therapy available in patients with type 1 HRS, although pentoxifylline may be effective to treat HRS in patients with cirrhosis and ascites. In patients with gastric varices, primary prophylaxis with cyanoacrylate may decrease the probability of gastric variceal hemorrhage compared to nonselective beta-blockers. In patients with esophageal varices without bleeding, prophylaxis with variceal ligation or beta-blockers was similar in terms of bleeding, mortality, and adverse events. Erythromycin given 30 min prior to endoscopic evaluation in suspected EVH was associated with an overall benefit in visibility, duration of the procedure and length of hospital stay. Refinement in clinical management strategies for patients with cirrhosis and its complications appears to continue to contribute to improved patient outcomes.Keywords
This publication has 16 references indexed in Scilit:
- Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: A cross-over studyJournal of Hepatology, 2011
- Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamicsJournal of Hepatology, 2011
- A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathyEuropean Journal of Gastroenterology & Hepatology, 2011
- Rifaximin Improves Driving Simulator Performance in a Randomized Trial of Patients With Minimal Hepatic EncephalopathyGastroenterology, 2011
- Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C TrialClinical Gastroenterology and Hepatology, 2010
- Clinical Pharmacology of Portal HypertensionGastroenterology Clinics of North America, 2010
- Deleterious Effects of Beta-Blockers on Survival in Patients With Cirrhosis and Refractory Ascites†,‡Hepatology, 2010
- Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: Results of a randomized controlled trialJournal of Hepatology, 2010
- Use of Sirolimus in Liver Transplant Recipients with Renal Insufficiency: A Systematic Review and Meta-AnalysisHepatology, 2010
- Rifaximin Treatment in Hepatic EncephalopathyNew England Journal of Medicine, 2010